Home  /  Resource Library  /  Pirtobrutinib in Post-cBTKi CLL/SLL: 30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Pirtobrutinib in Post-cBTKi CLL/SLL: 30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

ASH 2023